NXTC

NextCure, Inc. (NXTC) | Rumor.io

NextCure

NXTC

Attention (50-day avg)0%

Attention rank (50-day avg)#2,673

Bullish sentiment (50-day avg)95%

Price to earnings ratio-0.26

Market capitalization23.3M

Earnings per share-8.28

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-55.8M

Social

What share of all stock conversation is about NXTC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% +0

Aug 12

$NXTC has reached a new high of $8.72, up from $8, and has been recommended by some market analysts.
NextCure, Inc. is merging with Avere Therapeutics, a private portfolio holding, in a reverse merger.
$NXTC has shown significant price movement, with a 13.7% increase in one day, and is being watched by market analysts for further potential.

Generated by AI

Sentiment

Of the messages about NXTC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +4.81	88.98% +2.98
Bearish	—	—	0% -4.81	11.02% -2.98

Bullish· Jul 17

The company's management team is highly capable and experienced, which could lead to a surge in the stock's value.
A new product is poised to make a strong market impact, which could contribute to a significant increase in the stock's price.
The stock has formed a double bottom pattern, which is a bullish sign indicating a potential reversal in the stock's trend.

Bearish· Jul 17

$NXTC is expected to drop to $5.50 and then $5.25, with a slow and steady decline.
The asset's volume is drying up, which may indicate a lack of buying interest.
A potential bear trap is being set up, with the possibility of a fake 5-10% pop followed by a decline.

Generated by AI

Topics

Of the messages about NXTC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	62.04%
Technical Analysis	—	—	—	26.83%
Analysts	—	—	—	5.41%
Macro	—	—	—	4.5%
Controversies	—	—	—	1.22%
Earnings	—	—	—	0%

Announcements· Jul 14

NextCure, Inc. (NXTC) has agreed to an all-stock merger with Avere Therapeutics, with the combined company expected to trade as AVRX following the close.
The merger is supported by a concurrent $320 million private financing, which will fund the development of Avere's once-weekly oral IL-23 therapy, AVR-001.
NextCure shareholders will receive a significant portion of the merged company's equity, with the possibility of up to 90% of the cash dividend through Contingent Value Rights (CVR) if NextCure's existing drug assets are successfully out-licensed.

Technical Analysis· Jul 14

$NXTC is expected to experience a strong reversal to the upside, with potential for a breakout above $15.
The chart for $NXTC resembles a similar pattern to VEEE when it bottomed at $18, with potential for a significant increase in value.
Key levels for $NXTC include breaking and holding above $9.00, $10.00, $11.00, $12.00, $15.00, $50.00, and $500.00 for each new level up.

Generated by AI

Community

Of the messages about NXTC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	93.33%	35.04%
Newcomers	—	100%	6.67%	64.96%

Aug 12

Some newcomers are holding onto NextCure, Inc. despite its slow price movement, hoping it could get rowdy.
The merger between Avere Therapeutics and NextCure, Inc. has been identified as a potential opportunity for investment.
NextCure, Inc. has been mentioned as a potential beneficiary of the China-mania phenomenon, with some speculating it could be the next target for a Chinese short squeeze.

Generated by AI

News

NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma - Slideshow (NASDAQ:NXTC) 2026-06-02

14d agoSeeking Alpha

NextCure stock rating reiterated at Buy by H.C. Wainwright

1mo agoInvesting.com

Simcere Zaiming sells $184,800 of NextCure stock

1mo agoInvesting.com

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

As previously announced on July 14, 2026, Avere and NextCure, Inc. have entered into a definitive merger agreement for an all-stock transaction. The $500 million Private Placement consists of common stock and pre-funded warrants to purchase common stock. Participants in the Private Placement included Venrock Healthcare Capital Partners, General...

1mo agoNasdaq

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 – Company Announcement

1mo agoFinancial Times

NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results

BELTSVILLE, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today provided a business update and reported...

1mo agoBarchart.com

Also Discussed

Investors talking about NXTC also mention

#	Name	Attention
1	Alector Inc.ALEC	0%new
2	KRTX - Karuna Therapeutics, Inc.	——
3	Lucas GC Limited Ordinary SharesLGCL	0%0
4	Galapagos NV American Depositary ReceiptGLPG	0%0
5	Assembly Biosciences Inc.ASMB	0%new
6	CytomX Therapeutics, Inc.CTMX	0%0
7	KRON - Kronos Bio, Inc.	——
8	Passage Bio Inc.PASG	0%0
9	ASLN - ASLAN Pharmaceuticals Limited	——
10	Zhongchao Inc. Class A Ordinary SharesZCMD	0%new

NextCure, Inc.

Healthcare
Biotechnology

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing immunomedicines for cancer and other immune-related diseases. The company’s work centers on identifying biological pathways, biomarkers, and immune-cell interactions within the tumor microenvironment to create therapies for patients whose cancers do not respond well to current treatments. Its current programs emphasize targeted approaches such as antibody-drug conjugates and other differentiated mechanisms of action designed to address difficult-to-treat tumors. NextCure also uses its FIND-IO discovery platform to help identify novel immune targets and support pipeline development. Headquartered in Beltsville, Maryland, NextCure plays a specialized role in the oncology and immunology markets by advancing experimental therapies intended to improve treatment options for patients with limited alternatives.

Website

Location

9000 Virginia Manor Road

Beltsville, MD, 20705

United States

Social

What share of all stock conversation is about NXTC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% +0

Aug 12

$NXTC has reached a new high of $8.72, up from $8, and has been recommended by some market analysts.
NextCure, Inc. is merging with Avere Therapeutics, a private portfolio holding, in a reverse merger.
$NXTC has shown significant price movement, with a 13.7% increase in one day, and is being watched by market analysts for further potential.

Generated by AI

Sentiment

Of the messages about NXTC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +4.81	88.98% +2.98
Bearish	—	—	0% -4.81	11.02% -2.98

Bullish· Jul 17

The company's management team is highly capable and experienced, which could lead to a surge in the stock's value.
A new product is poised to make a strong market impact, which could contribute to a significant increase in the stock's price.
The stock has formed a double bottom pattern, which is a bullish sign indicating a potential reversal in the stock's trend.

Bearish· Jul 17

$NXTC is expected to drop to $5.50 and then $5.25, with a slow and steady decline.
The asset's volume is drying up, which may indicate a lack of buying interest.
A potential bear trap is being set up, with the possibility of a fake 5-10% pop followed by a decline.

Generated by AI

Topics

Of the messages about NXTC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	62.04%
Technical Analysis	—	—	—	26.83%
Analysts	—	—	—	5.41%
Macro	—	—	—	4.5%
Controversies	—	—	—	1.22%
Earnings	—	—	—	0%

Announcements· Jul 14

NextCure, Inc. (NXTC) has agreed to an all-stock merger with Avere Therapeutics, with the combined company expected to trade as AVRX following the close.
The merger is supported by a concurrent $320 million private financing, which will fund the development of Avere's once-weekly oral IL-23 therapy, AVR-001.
NextCure shareholders will receive a significant portion of the merged company's equity, with the possibility of up to 90% of the cash dividend through Contingent Value Rights (CVR) if NextCure's existing drug assets are successfully out-licensed.

Technical Analysis· Jul 14

$NXTC is expected to experience a strong reversal to the upside, with potential for a breakout above $15.
The chart for $NXTC resembles a similar pattern to VEEE when it bottomed at $18, with potential for a significant increase in value.
Key levels for $NXTC include breaking and holding above $9.00, $10.00, $11.00, $12.00, $15.00, $50.00, and $500.00 for each new level up.

Generated by AI

Community

Of the messages about NXTC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	93.33%	35.04%
Newcomers	—	100%	6.67%	64.96%

Aug 12

Some newcomers are holding onto NextCure, Inc. despite its slow price movement, hoping it could get rowdy.
The merger between Avere Therapeutics and NextCure, Inc. has been identified as a potential opportunity for investment.
NextCure, Inc. has been mentioned as a potential beneficiary of the China-mania phenomenon, with some speculating it could be the next target for a Chinese short squeeze.

Generated by AI

NextCure

Social

Aug 12

Bullish· Jul 17

Bearish· Jul 17

Announcements· Jul 14

Technical Analysis· Jul 14

Aug 12

NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma - Slideshow (NASDAQ:NXTC) 2026-06-02

NextCure stock rating reiterated at Buy by H.C. Wainwright

Simcere Zaiming sells $184,800 of NextCure stock

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 – Company Announcement

NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results

Also Discussed

NextCure, Inc.

Company Information

Location

NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma - Slideshow (NASDAQ:NXTC) 2026-06-02

NextCure stock rating reiterated at Buy by H.C. Wainwright

Simcere Zaiming sells $184,800 of NextCure stock

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 – Company Announcement

NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results

Also Discussed

Social

Aug 12

Bullish· Jul 17

Bearish· Jul 17

Announcements· Jul 14

Technical Analysis· Jul 14

Aug 12